Physician profile
Brent Grass
NPI 1295353183
$11,662.97
in general payments reported to CMS, 2019-2025
47 companies · $2,358 in 2025
The $2,358 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,414 · 2022: $2,402 · 2023: $2,144 · 2024: $2,345 · 2025: $2,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,757 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,757.04 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,026.51 | 2021-2025 | |
| Novo Nordisk INC | $1,703.16 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,382.15 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $737.92 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $672.63 | 2021-2025 | |
| Lilly USA, LLC | $667.67 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $475.91 | 2021-2023 | Jardiance, Spiriva Respimat, Tradjenta |
| Astellas Pharma US INC | $324.68 | 2021-2025 | Veozah, Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $311.63 | 2021-2024 | Ajovy |
| Sanofi-Aventis U.S. LLC | $279.32 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $278.54 | 2021-2025 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $256.95 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $246.06 | 2021-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.39 | 2021-2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $211.91 | 2021 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $209.66 | 2022 | |
| Exact Sciences Corporation | $208.74 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $160.93 | 2021-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $152.83 | 2023-2025 | Gemtesa |
| Optinose US, INC. | $109.96 | 2025 | |
| Phathom Pharmaceuticals, INC. | $105.33 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $104.52 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $91.53 | 2022-2023 | Quviviq |
| Abbott Laboratories | $87.48 | 2021-2025 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $86.52 | 2022-2024 | |
| Aimmune Therapeutics, INC. | $67.57 | 2024-2025 | Zenpep |
| Currax Pharmaceuticals LLC | $44.50 | 2023-2024 | Contrave |
| Inspire Medical Systems, INC. | $42.21 | 2025 | Inspire |
| Xeris Pharmaceuticals, INC. | $38.97 | 2023 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $37.44 | 2025 | Auvelity |
| Ascensia Diabetes Care US INC. | $34.59 | 2024-2025 | |
| Aytu Biopharma, INC. | $30.74 | 2024 | Karbinal |
| Medtronic, INC. | $23.38 | 2025 | Inceptiv |
| Amgen INC. | $22.84 | 2024 | Krystexxa |
| Gilead Sciences, INC. | $20.72 | 2023 | |
| Vbi Vaccine (Delaware) INC. | $20.45 | 2023 | Prehevbrio |
| E.R. Squibb & Sons, L.L.C. | $20.39 | 2025 | Camzyos |
| Dynavax Technologies Corporation | $19.90 | 2023 | Heplisav-B |
| Exeltis, USA INC. | $16.64 | 2024 | Slynd |
| Neos Therapeutics, LP | $15.62 | 2025 | Adzenys Xr-Odt |
| Hologic Sales and Service, LLC | $15.30 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.90 | 2021 | |
| Seqirus USA INC | $13.22 | 2021 | |
| Organon LLC | $12.30 | 2025 | Nexplanon |
| Almatica Pharma LLC | $12.25 | 2022 | |
| Bausch Health US, LLC | $11.94 | 2022 | |
| Corium, LLC | $7.17 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Grass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.